U54CA277843
Cooperative Agreement
Overview
Grant Description
The Avanço Research Consortium: A Mozambique/Brazil/Texas Alliance to Advance Novel and Affordable Technologies for the Prevention and Diagnosis of Cervical Cancer in Women Living with HIV - Abstract
The overall vision of the Avanço Research Consortium is to establish sustainable infrastructure to develop research programs focused on HIV-associated malignancies in Brazil and Mozambique. The research theme chosen for this U54 HIV-associated Malignancy Research Center (HAMRC) is to develop novel, low-cost and technologically feasible approaches for cervical cancer screening, diagnosis, and treatment in women living with HIV (WLWH) in low- and middle-income countries (LMICs).
This HAMRC will be a collaboration between institutions in the US, Mozambique, and Brazil and includes investigators with expertise in HIV/AIDS, cervical cancer, bioengineering, pathology, epidemiology, and behavioral science. The investigators have several ongoing scientific and clinical collaborations which include projects across all three countries.
Our proposal addresses the NIH priority: to address HIV-associated comorbidities, coinfections, and complications, which includes malignancies as a category. HIV infection is a known risk factor for cervical cancer, with WLWH having an approximate 6-fold increased risk of developing cervical cancer.
The overall goals of the Avanço Research Consortium include:
1) Establish sustainable research infrastructure to perform multi-institutional research studies related to HIV-associated malignancies across institutions in the US, Brazil, and Mozambique. We will build a comprehensive research program focused on identifying novel, low-cost and technologically feasible approaches for the prevention, diagnosis, and treatment of cervical cancer in WLWH in LMICs.
2) Conduct two research projects that advance the development of promising low-cost technologies focused on the diagnoses of high-grade cervical dysplasia and invasive cervical cancer among WLWH.
3) Facilitate and enhance the professional development of junior investigators to conduct HIV-associated malignancy research in Mozambique and Brazil. Through our Developmental Core and Shared Resource Core, we will build research capacity and collaboration through formal research training courses, pilot project funding, and implementation of a Project ECHO® program for research capacity building focused on mentoring and supporting early-career investigators.
The overall vision of the Avanço Research Consortium is to establish sustainable infrastructure to develop research programs focused on HIV-associated malignancies in Brazil and Mozambique. The research theme chosen for this U54 HIV-associated Malignancy Research Center (HAMRC) is to develop novel, low-cost and technologically feasible approaches for cervical cancer screening, diagnosis, and treatment in women living with HIV (WLWH) in low- and middle-income countries (LMICs).
This HAMRC will be a collaboration between institutions in the US, Mozambique, and Brazil and includes investigators with expertise in HIV/AIDS, cervical cancer, bioengineering, pathology, epidemiology, and behavioral science. The investigators have several ongoing scientific and clinical collaborations which include projects across all three countries.
Our proposal addresses the NIH priority: to address HIV-associated comorbidities, coinfections, and complications, which includes malignancies as a category. HIV infection is a known risk factor for cervical cancer, with WLWH having an approximate 6-fold increased risk of developing cervical cancer.
The overall goals of the Avanço Research Consortium include:
1) Establish sustainable research infrastructure to perform multi-institutional research studies related to HIV-associated malignancies across institutions in the US, Brazil, and Mozambique. We will build a comprehensive research program focused on identifying novel, low-cost and technologically feasible approaches for the prevention, diagnosis, and treatment of cervical cancer in WLWH in LMICs.
2) Conduct two research projects that advance the development of promising low-cost technologies focused on the diagnoses of high-grade cervical dysplasia and invasive cervical cancer among WLWH.
3) Facilitate and enhance the professional development of junior investigators to conduct HIV-associated malignancy research in Mozambique and Brazil. Through our Developmental Core and Shared Resource Core, we will build research capacity and collaboration through formal research training courses, pilot project funding, and implementation of a Project ECHO® program for research capacity building focused on mentoring and supporting early-career investigators.
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding Agency
Funding Agency
Place of Performance
Houston,
Texas
770304000
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 124% from $933,946 to $2,090,784.
The Univeristy Of Texas M.D. Anderson Cancer Center was awarded
Avanço Consortium: Advancing Cervical Cancer Tech for WLWH
Cooperative Agreement U54CA277843
worth $2,090,784
from Fogarty International Center in August 2023 with work to be completed primarily in Houston Texas United States.
The grant
has a duration of 5 years and
was awarded through assistance program 93.989 International Research and Research Training.
The Cooperative Agreement was awarded through grant opportunity U.S. and Low- and Middle-Income Country (LMIC) HIV-Associated Malignancy Research Centers (U54 Clinical Trial Optional).
Status
(Ongoing)
Last Modified 9/5/24
Period of Performance
8/1/23
Start Date
7/31/28
End Date
Funding Split
$2.1M
Federal Obligation
$0.0
Non-Federal Obligation
$2.1M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for U54CA277843
Transaction History
Modifications to U54CA277843
Additional Detail
Award ID FAIN
U54CA277843
SAI Number
U54CA277843-4064276598
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75NC00 NIH NATIONAL CANCER INSTITUTE
Funding Office
75NF00 NIH FOGARTY INTERNATIONAL CENTER
Awardee UEI
S3GMKS8ELA16
Awardee CAGE
0KD38
Performance District
TX-09
Senators
John Cornyn
Ted Cruz
Ted Cruz
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| National Cancer Institute, National Institutes of Health, Health and Human Services (075-0849) | Health research and training | Grants, subsidies, and contributions (41.0) | $1,011,446 | 98% |
Modified: 9/5/24